These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Nationwide survey of palivizumab for respiratory syncytial virus prevention in Japanese children with congenital heart disease. Saji T, Nakazawa M, Harada K. Pediatr Infect Dis J; 2008 Dec; 27(12):1108-9. PubMed ID: 18978515 [Abstract] [Full Text] [Related]
8. [Prophylaxis of respiratory syncytial virus infections with palivizumab]. Danés Carreras I, Arnau De Bolós JM. An Esp Pediatr; 2002 Apr; 56(4):289-91. PubMed ID: 11927094 [No Abstract] [Full Text] [Related]
9. Palivizumab prophylaxis: how to compare pre- and post-prophylaxis eras? Korppi M. Pediatr Pulmonol; 2007 Jul; 42(7):660; author reply 661. PubMed ID: 17534973 [No Abstract] [Full Text] [Related]
10. Severe respiratory syncytial virus bronchiolitis: epidemiologic variations associated with the initiation of palivizumab in severely premature infants with bronchopulmonary dysplasia. Grimaldi M, Gouyon B, Michaut F, Huet F, Gouyon JB, Burgundy Perinatal Network. Pediatr Infect Dis J; 2004 Dec; 23(12):1081-5. PubMed ID: 15626942 [Abstract] [Full Text] [Related]
20. Respiratory syncytial virus: different criteria for palivizumab use in different areas? Mitchell I. South Med J; 2007 Jul; 100(7):661-2. PubMed ID: 17639741 [No Abstract] [Full Text] [Related] Page: [Next] [New Search]